Key Points
- Halozyme CEO Helen Torley sold 10,000 shares on June 3 at an average price of $69.07, totaling about $690,700. The sale was made under a pre-arranged Rule 10b5-1 plan.
- Torley has been consistently trimming her stake in recent weeks, including additional sales on June 1, May 13, May 12, April 6, and April 2. After the latest sale, she still owned 767,780 shares valued at roughly $53.0 million.
- Halozyme’s fundamentals and analyst sentiment remain solid: the company beat quarterly EPS and revenue estimates, raised FY2026 guidance, and analysts currently have a Moderate Buy consensus with a $81.60 price target.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,030,564.60. This represents a 1.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00.
- On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00.
- On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00.
- On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.50, for a total transaction of $635,000.00.
- On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00.
Halozyme Therapeutics Price Performance
HALO stock opened at $69.82 on Thursday. The company has a fifty day moving average price of $66.44 and a 200-day moving average price of $68.71. The company has a market capitalization of $8.28 billion, a P/E ratio of 25.12, a PEG ratio of 0.27 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 52-week low of $51.06 and a 52-week high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company's revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current year.
Halozyme Therapeutics News Summary
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: Zacks Research raised earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, suggesting improving profit expectations for Halozyme Therapeutics. Halozyme Therapeutics article
- Positive Sentiment: Analysts now see stronger earnings in several quarters, including Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which may reinforce the stock’s valuation outlook. Halozyme Therapeutics article
- Neutral Sentiment: There was also a small increase in one near-term estimate for Q4 2026, while Q2 2026 was trimmed slightly and Q1 2028 was revised lower, indicating a mostly constructive but not uniformly higher forecast profile. Halozyme Therapeutics article
- Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were executed under pre-arranged 10b5-1 plans, which usually makes them less concerning to investors than discretionary selling. Halozyme Therapeutics article
Institutional Investors Weigh In On Halozyme Therapeutics
A number of large investors have recently bought and sold shares of HALO. DLD Asset Management LP grew its holdings in Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company's stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares during the period. Norges Bank bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $128,201,000. William Blair Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at $124,031,000. Voloridge Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the third quarter valued at $77,587,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Halozyme Therapeutics in the second quarter valued at $51,295,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the stock. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Wednesday, April 29th. UBS Group reiterated a "buy" rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. Morgan Stanley decreased their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, May 16th. Finally, TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $81.60.
View Our Latest Analysis on Halozyme Therapeutics
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
